Pharmaceutical industry discursives and the marketization of nursing work: A case example

Nursing Philosophy

Volumn 12, Issue 3, 2011, Pages 214-228

  Springer, Rusla Anne ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Foucault; Heterodiscursive spaces; Marketization; Multiple sclerosis; Persuasion; Self technologies; Subjectivation; Surveillance

Indexed keywords

ARTICLE; DRUG INDUSTRY; ETHICS; FINANCIAL MANAGEMENT; HUMAN; MEDICAL ETHICS; MORALITY; MULTIPLE SCLEROSIS; NURSE PATIENT RELATIONSHIP; NURSING; PHILOSOPHY; PROFESSIONAL PRACTICE;

DRUG INDUSTRY; ETHICS, NURSING; HUMANS; MARKETING OF HEALTH SERVICES; MORALS; MULTIPLE SCLEROSIS; NURSE-PATIENT RELATIONS; PHILOSOPHY, NURSING; PROFESSIONAL AUTONOMY;

EID: 79958806018     PISSN: 14667681     EISSN: 1466769X     Source Type: Journal    
DOI: 10.1111/j.1466-769X.2011.00498.x     Document Type: Article

References (87)

1. Akerstrom Andersen N. (2003) Discursive Analytical Strategies: Understanding Foucault, Koselleck, Laclau, Luhmann. The Policy Press, Bristol, UK.
2. Angell M. (2004) The Truth about the Drug Companies. Random House, New York, NY.
3. Barnes L. (2000) The social production of an enterprise clinic: nurses, clinical pathway guidelines and contemporary healthcare practices. Nursing Inquiry, 7, 200-208.
4. Brennan T.A., Rothman D.J., Blank L. etal. (2006) Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. The Journal of the American Medical Association, 295(4), 429-433.
5. Breslin J.M., MacRae S.K., Bell J., Singer P.A. & the University of Toronto Joint Centre for Bioethics Clinical Ethics Group (2005) Top 10 health care ethics challenges facing the public: views of Toronto bioethicists. BMC Medical Ethics, 6(5), 1-8. DOI: 10.ll86/1472-6939-6-5. Available at:.
6. Brody H. (2005) The company we keep: why physicians should refuse to see pharmaceutical representatives. Annals of Family Medicine, 3(1), 82-86.
7. Brownlee S. (2007) Overtreated: Why Too Much Medicine Is Making Us Sicker and Poorer. Bloomsbury, New York, NY.
8. Burman E. (1991) What discourse is not. Philosophical Psychology, 4(3), 325-343.
9. Campbell E.G. (2007) Doctors and drug companies - scrutinizing influential relationships. New England Journal of Medicine, 357(18), 1796-1797.
10. Canada's Research Based Pharmaceutical Companies (Rx&D) (2008) Principles & Integrity, Code of Conduct. 55 Metcalfe Street, Suite 1220, Ottawa, Ontario.
11. Canadian Nurses Association (2008) Code of Ethics for Registered Nurses: 2008 Centennial Edition. Author, Ottawa.
12. Caon C., Din M., Ching W., Tselis A., Lisak R. & Khan O. (2006) Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. European Journal of Neurology, 13, 471-474.
13. Carpenito L.J. (2000) Nursing Diagnosis. Application to Clinical Practice, 8th edn. Lippincott, Philadelphia, PA.
14. Ceci C. (2006) 'What she says she needs doesn't make a lot of sense': seeing and knowing in a field study of home-care case management. Nursing Philosophy, 7, 90-99.
15. Chaudhuri A. (2005) Interferon beta, progressive MS, and brain atrophy. The Lancet Neurology, 4(4), 208-209.
16. Cheek J. & Rudge T. (1994) Inquiry into nursing as textually mediated discourse. In: Advances in Methods of Inquiry for Nursing (ed. P.L. Chinn), pp. 59-67. An Aspen Publication, Aspen Publishers, Inc, Gaithersburg, MD.
17. Chewing B. & Sleath B. (1996) Medication decision-making and management: a client centered model. Sociology Science Medicine, 42(3), 389-398.
18. Chinn P.L. (1999) Gender and nursing science. In: Perspectives on Philosophy of Science in Nursing: An Historical and Contemporary Anthology (eds E.C. Polifroni & M. Welch), pp. 462-466. Lippincott, Philadelphia, PA; New York, NY; Baltimore, MD.
19. Clarke S. & O'Connor P. (2004) A spire of excellence: MS care and research is a priority at St. Michael's hospital. Compass, 5(2), 6.
20. Crock E. (2009) Ethics of pharmaceutical company relationships with the nursing profession: no free lunch...And no more pens? Contemporary Nurse, 33(2), 202-209.
21. Davies B., Browne J., Gannon S., Honan E., Laws C., Mueller-Rockstroph B. & Patersen E.B. (2004). The ambivalent practices of reflexivity. Qualitative Inquiry, 10(3), 260-389.
22. Dennis L., Namey M., Costello K. etal. (2004) Long-term treatment optimization and individuals with multiple sclerosis using disease-modifying therapies: a nursing approach. Journal of Neuroscience Nursing, 36(1), 10-23.
23. Dorfman L. (2006) Optic neuritis. New England Journal of Medicine, 355(2), 212.
24. Dukes G. (2006) The Law and Ethics of the Pharmaceutical Industry. Elsevier, Oxford; UK.
25. Ebers G.C. (2001) Preventing multiple sclerosis? The Lancet, 357, 1547.
26. Erlen J.A. (1998) Treatment decision-making: who should decide? Orthopaedic Nursing, 17(4), 60-66.
27. Filippini G., Munari L., Incorvaia B. etal. (2003) Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet, 362, 545-552.
28. Foucault M. (1972) The Archaeology of Knowledge. Translated from the French by A. M. Sheridan Smith. Pantheon Books, A Division of Random House, New York, NY.
29. Foucault M. (1977) Discipline and Punish: The Birth of the Prison. Translated from the French by Alan Sheridan. Pantheon Books, New York, NY.
30. Foucault M. (1978) Colloqui con Foucault. Interview with Duccio Trombadori (Italian). Translated from Italian by R. James Goldstein and James Cascaito as Remarks on Marx (NY: Semiotext (e)). Available at:.
31. Foucault M. (1980) Two lectures. In: Power/Knowledge: Selected Interviews and Other Writings 1972-1977 (ed. C. Gordon), pp. 78-108. The Harvester Press, Pantheon Books, New York, NY.
32. Foucault M. (1994) The Order of Things: Archaeology of the Human Sciences. Vintage Books, A Division of Random House Inc. New York. (Original Publication, 1970).
33. Gadow S. (1980) Existential advocacy: philosophical foundations of nursing. In: Nursing: Images and Ideals. Opening Dialogue with the Humanities (eds S. Siker & S. Gadow), pp. 41-50. Springer Publishing Co., New York, NY.
34. Goodin D.S. (2004a) Disease-modifying therapy in MS: a critical review of the literature. Part I: analysis of clinical trial errors. Journal of Neurology, 1503, 3-11.
35. Goodin D.S. (2004b) Disease-modifying therapy in MS: a critical review of the literature. Part II: assessing efficacy and dose-response. Journal of Neurology, 1508, 50-56.
36. Hanley G. & Morgan S. (2009) Chronic catastrophes: exploring the concentration and sustained nature of ambulatory prescription drug expenditures in the population of British Columbia, Canada. Social Science & Medicine, 68(5), 919.
37. Harris C. (2005) Adherence in long-term MS therapy: clinical insights from a nursing perspective. International Journal of MS Care, (February Supplement), 19-21.
38. Holman H. & Lorig K. (2000) Patients as partners in managing chronic disease: partnership is a prerequisite for effective and efficient health care. British Medical Journal, 320, 526-527.
39. Jutel A. & Menkes D.B. (2008) Soft targets: nurses and the pharmaceutical industry. PLoS Medicine, 5(2), 0193-0198.
40. Kagan P.N., Smith M.C., Cowling W.R. & Chin P.L. (2009) A nursing manifesto: an emancipator call for knowledge development, conscience, and praxis. Nursing Philosophy, 11, 67-84.
41. Kassirer J.P. (2005) On the Take: How Medicine Complicity with Big Business Can Endanger Your Health. Oxford University Press, New York, New York 10016.
42. Katz D., Caplan A.L. & Merz J.F. (2003) All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving. American Journal of Bioethics, 3(3), 39-47.
43. Kelly-Powell M.L. (1997) Personalizing choices: patients' experiences with making treatment decisions. Research in Nursing & Health, 20, 219-227.
44. Kohn A. (1986) Making and breaking the rules of science. In: False Prophets (ed. A. Kohn), pp. 1-11. Basil Blackwell, Oxford; UK.
45. Lagrange J., Ewald F. & Fontana A. (eds) (2003) Michel Foucault: Psychiatric Power. Lectures at the College De France 1973-74. English Series Editor, Arnold I. Davidson. Translated by Graham Burchell. Palgrave MacMillan, Picador, New York.
46. Lakeman R. (2010) Mental health nursing is not for sale: rethinking nursing's relationship with the pharmaceutical industry. Journal of Psychiatric and Mental Health Nursing, 17, 172-177.
47. Landefeld C.S. & Steinman M.A. (2009) The neurontin legacy - marketing through misinformation and manipulation. New England Journal of Medicine, 360(2), 103-106.
48. Lapierre Y., Lowden D. & Fullerton L. (2005) Aiming for the best care: the mcgill University Health Centre's MS program. Compass, 6, 9.
49. Latimer J. (1998) Organizing context: nurses' assessments of older people in an acute medical unit. Nursing Inquiry, 5, 43-57.
50. Lovell M.C. (1981) Silent but perfect 'partners': medicine's use and abuse of women. Advances in. Nursing Science, 3, 25-40.
51. Ludwin S.K. (2008) New support for MS researchers and the people they serve. Multiple Sclerosis Society of Canada. Available at:.
52. Lupton D. (1992) Discourse analysis: a new methodology for understanding the ideologies of health and illness. Australian Journal of Public Health, 16(2), 145-150.
53. MacLean H.J. & Freedman M.S. (2008) Multiple sclerosis: following clues from cause to cure. Lancet Neurology, 8(1), 6-8.
54. Mallarkey G. (2008) What are the therapeutic advances in neurology? Opinions from world experts. Therapeutic Advances in Neurological Disorders, 1(1), 5-12. DOI: 10.1177/1756285608094210.
55. Mohr D.C., Goodkin D., Likosky W. etal. (1996) Therapeutic expectations of patients with multiple sclerosis upon initiating IFNB-1b: relationship to adherence to treatment. Multiple Sclerosis, 2, 222-226.
56. Morgante L., Hartley G., Lowden D., Namey M., La Rocca T. & Shilling J. (2006) Decision-making in multiple sclerosis: theory to practice. International Journal of MS Care, 8, 113-120.
57. Moynihan R. & Cassels A. (2005) Selling Sickness: How the World's Biggest Pharmaceutical Companies Are Turning Us All into Patients. Greystone Books. Douglas & McIntyre Publishing Group, Vancouver; Toronto.
58. Muff J. (1988) Of images and ideals: a look at socialization and sexism in nursing. In: Images of Nurses, Perspectives from History, Art, and Literature. A.H. Jones (ed.), pp. 197-220. University of Pennsylvania Press, Philadelphia, PA.
59. Munari L., Lovati R. & Boiko A. (2004) Therapy with glatiramer acetate for multiple sclerosis. The Cochrane Library, 1, 1-25.
60. Murray T.J. (2003) A brighter future: the Dalhousie MS research unit will help us get there. Compass, 4(2), 6.
61. Murray T.J. (2006) Diagnosis and treatment of multiple sclerosis. BMJ, 332, 525-527.
62. National Multiple Sclerosis Society (2007) Disease management consensus statement. Expert pinion paper from the National Clinical Advisory Board of the National Multiple Sclerosis Society. Professional Resource Center, 73 Third Avenue, New York, NY, 10017-3288.
63. O'Farrell C. (2005) Michel Foucault. Sage Publications, London; Thousand Oaks, CA; New Delhi.
64. Pajnkihar M. (2009) Nurses' (Un) partner-like relations with clients. Nursing Ethics, 16(1), 43-56. DOI: 10.1177/0969733008097989.
65. Paterson B. (2001) Myth of empowerment in chronic illness. Journal of Advanced Nursing, 34(5), 574-581.
66. Paterson B.L., Russell C. & Thorne S. (2001) Critical analysis of everyday self-care decision making in chronic illness. Journal of Advanced Nursing, 35(3), 335-341.
67. Pellegrino E. & Thomasma D.C. (1981) A Philosophical Basis of Medical Practice: A Philosophy and Ethic of Healing Professions. Oxford University Press, New York, NY.
68. Pittock S.J., Weinshenker B.G., Noseworthy J.H. etal. (2006) Not every patient with multiple sclerosis should be treated at time of diagnosis. Archives of Neurology, 63, 611-614.
69. Purkis M.E. (1997) The 'social determinants' of practice? A critical analysis of the discourse of health promotion. Canadian Journal of Nursing Research, 29(1), 47-62.
70. Reverby S. (1987) A caring dilemma: womanhood and nursing in historical perspective. Nursing Research, 36(1), 5-11.
71. Rice G. & Ebers G. (1998) Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease? Archives of Neurology, 55, 1578-1580.
72. Rice G.P.A., Incorvaia B., Munari I. etal. (2001) Interferon in relapsing-remitting multiple sclerosis (Cochrane Review). The Cochrane Database of Systematic Reviews, 4, Art. No.: CD002002. DOI: 10.1002/14651858.CD002002.
73. Robinson J. (2001) Prescription Games: Money, Ego and Power inside the Global Pharmaceutical Industry. Simon & Shuster. A Viacom Company, Simon Schuster UK Ltd. London.
74. Schafer A. (2004) Biomedical conflicts of interest: a defense of the sequestration thesis - learning from the cases of Nancy Olivieri and David Healy. Journal of Medical Ethics, 30, 8-24.
75. Segal J.Z. (2005) Health and the Rhetoric of Medicine. Southern Illinois University Press, Carbondale, IL.
76. Springer R.A. (2005) Exploring Decisional Conflict around Disease Modifying Therapy in Multiple Sclerosis. Library and Archives Canada=Bibliotheque et Archives Canada, Ottawa. Canadiana: 20052129039, ISBN: 0612976580.
77. Springer R.A. (2010) Pharmaceutical Industry Discursives and the Subjectivities of Physicians, Nurses and Multiple Sclerosis Patients: A Foucauldian Dispositive Analysis. Library and Archives Canada=Bibliotheque et Archives Canada, Ottawa. Canadiana: 2010212695X. ISBN: 9780494544815.
78. Steinman M.A. & Baron R.B. (2007) Is continuing medical education a drug-promotion tool? Canadian Family Physician, 53, 1650-1653.
79. Tarlier D.S. (2004) Beyond caring: the moral and ethical bases of responsive nurse-patient relationships. Nursing Philosophy, 5, 230-241.
80. Teva Neuroscience (2002) MS Therapy Initiation Kit: Why Copaxone Therapy? Teva neuroscience G.P. - SENC., Montreal, QC. H3A 3LB.
81. The Canadian MS Clinics Network Multiple Sclerosis Preceptorship (2000) Learn more about it. Serono Symposia USA, November 23-26, 2000. Ottawa, Ontario Canada.
82. The IFNB Multiple Sclerosis Study Group (1993) Interferon 1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology, 43, 655-661.
83. Treanor P. (2011) Neoliberalism: origins, theory, definition. Available at:.
84. Tremlett H., Paty D. & Devonshire V. (2006) Disability progression in multiple sclerosis is slower than previously reported. Neurology, 66, 172-177.
85. Van Dijk T.A. (1997) Discourse As Structure and Process. Discourse Studies: A Multidisciplinary Introduction, Volume 1. Sage Publications, London; Thousand Oaks, CA; New Delhi.
86. Williams S.J., Gabe J. & Davis P. (eds) (2009) Pharmaceuticals and Society: Critical Discourses and Debates. Wiley-Blackwell, Chichester, West Sussex, UK.
87. Wilson H.V. (2001) Power and partnership: a critical analysis of the surveillance discourses of child health nurses. Journal of Advanced Nursing, 36(2), 294-301.